Se încarcă compania
Just reported
Q3 2026 results
From Harvard Bioscience's results release of 10 noiembrie 2026; its quarterly report has since been filed.
Revenue
Actual
22,2M USD
+7,8 % y/y
-2,3 % q/qGuided
21,8M USD
midpoint
Within guide+1,8 %EPS, GAAP
Actual
-0,58 USD
Guided
—
No guide given
Operating income, GAAP
Actual
-1,2M USD
Guided
—
No guide given
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
The full earnings report →Keep exploring
The themes Harvard Bioscience is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Highest-graded in Medical Instruments and Supplies
Graded A or B and worth $2B or more: A first, then the largest.
ISRGIntuitive Surgical, Inc.153,8B USDA+
MDLNMedline Inc.51,9B USDA
ALCAlcon Inc.36,1B USDA
BLCOBausch & Lomb Corp7,5B USDA-
ATRCAtriCure, Inc.2,9B USDA
Grade rose recently in Healthcare
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher Corporation21 oct. 2026CBGraded C, now B
MCKMckesson Corporation4 nov. 2026BAGraded B, now A
CVSCVS Health Corp4 nov. 2026BAGraded B, now A
EWEdwards Lifesciences Corporation4 nov. 2026BAGraded B, now A
GEHCGE Healthcare Technologies Inc.28 oct. 2026CAGraded C, now A
Situațiile financiare complete →
Construit din raportările proprii ale Harvard Bioscience, Inc. la Comisia pentru Valori Mobiliare și Burse a SUA (SEC). Cifrele sunt cele raportate, iar istoricul pe acțiune este recalculat la baza de acțiuni de azi. Aceasta descrie o afacere — nu este consultanță de investiții și nu este o recomandare de cumpărare sau vânzare.
